The Relationship Between Ferroptosis and Cancer Progression

Cancer cells often exploit the mechanisms regulating ferroptosis to evade cell death and promote tumor survival. The ability of cancer cells to resist ferroptosis is linked to the dysregulation of the JAK/STAT signaling pathway, which can either promote or inhibit ferroptosis depending on the cellular context (Dai et al., 2025).

In cancers such as hepatocellular carcinoma, prostate cancer, and renal cell carcinoma, STAT3 activation inhibits ferroptosis by upregulating SLC7A11 and GPX4, which help maintain cellular redox balance and prevent oxidative damage (Dai et al., 2025). Conversely, in conditions like Sjogren’s syndrome and age-related macular degeneration, STAT1 activation can promote ferroptosis through the downregulation of SLC7A11, leading to increased oxidative stress and cell death (Dai et al., 2025).

Thus, understanding the dual role of JAK/STAT signaling in regulating ferroptosis is critical for developing therapeutic strategies to manipulate these pathways for cancer treatment.

Mechanisms of JAK2 and STAT3 in Ferroptosis Induction

The mechanisms by which JAK2 and STAT3 influence ferroptosis involve several interconnected processes related to cellular metabolism and oxidative stress management. Activation of the JAK2/STAT3 pathway can lead to the transcriptional regulation of genes involved in the antioxidant response, particularly those encoding for SLC7A11 and GPX4.

JAK2/STAT3 Pathway

The activation of the JAK2/STAT3 pathway occurs upon binding of cytokines like IL-6 to their respective receptors, leading to the phosphorylation of JAK2 and the subsequent phosphorylation and activation of STAT3. Once activated, STAT3 translocates to the nucleus, where it binds to the promoters of target genes, including those involved in controlling oxidative stress and ferroptosis (Dai et al., 2025).

• Stat3 and SLC7A11: In renal cell carcinoma, IL-6 activates the JAK2/STAT3 signaling pathway, leading to the upregulation of SLC7A11. This increased expression enhances cystine uptake, leading to higher glutathione (GSH) levels, which in turn prevents lipid peroxidation and ferroptosis (Dai et al., 2025).

• Stat3 and GPX4: Similarly, GPX4, an enzyme essential for detoxifying lipid peroxides, is regulated by STAT3. The inhibition of GPX4 expression through the downregulation of the JAK2/STAT3 pathway can significantly increase the susceptibility of cancer cells to ferroptosis (Dai et al., 2025).

The interplay between these regulatory pathways underscores the significance of JAK2 and STAT3 in influencing ferroptosis, particularly in the context of cancer progression.

Therapeutic Potential of Targeting JAK/STAT Pathway in Cancer

Targeting the JAK/STAT signaling pathway presents a promising therapeutic strategy to manipulate ferroptosis in cancer cells. By modulating this pathway, it may be possible to enhance the effectiveness of ferroptosis inducers, providing a new avenue for overcoming drug resistance in various cancers.

JAK Inhibitors

Several JAK inhibitors, such as Ruxolitinib and Tofacitinib, have already been approved for clinical use in treating conditions like myelofibrosis and rheumatoid arthritis. These inhibitors can potentially be repurposed to enhance ferroptosis in cancer cells by disrupting the JAK/STAT signaling cascade that promotes cell survival (Dai et al., 2025).

Combination Therapies

Combining JAK inhibitors with ferroptosis inducers, such as erastin or RSL3, may enhance therapeutic efficacy by promoting ferroptosis in resistant cancer cells. For instance, in hepatocellular carcinoma, combining JAK inhibitors with ferroptosis inducers could lead to increased lipid peroxidation and cell death, thereby improving treatment outcomes (Dai et al., 2025).

Moreover, the regulatory role of the JAK/STAT pathway in immune responses suggests that targeting this pathway could also enhance immunotherapy outcomes. By manipulating ferroptosis in tumor cells, immune evasion mechanisms could be disrupted, allowing for improved anti-tumor responses.

Implications of Ferroptosis Modulation in Disease Treatment

The modulation of ferroptosis through the JAK/STAT signaling pathway has significant implications for treating various diseases beyond cancer. For instance, in neurodegenerative diseases and inflammatory conditions, inducing ferroptosis may provide therapeutic benefits by eliminating damaged or dysfunctional cells.

Neurodegenerative Diseases

In neurodegenerative diseases like Alzheimer’s and Parkinson’s, the accumulation of oxidative stress and lipid peroxidation contributes to neuronal death. Targeting the JAK/STAT pathway to enhance ferroptosis in neurodegenerative conditions could facilitate the clearance of damaged cells and promote tissue regeneration (Dai et al., 2025).

Autoimmune Disorders

In autoimmune disorders, the regulation of ferroptosis may also play a role in modulating immune responses. For instance, in conditions like Sjogren’s syndrome, promoting ferroptosis in autoimmune effector cells could help alleviate tissue damage and improve disease outcomes (Dai et al., 2025).

Inflammatory Diseases

The relationship between the JAK/STAT pathway and ferroptosis highlights the potential for therapeutic interventions in inflammatory diseases. Targeting this pathway could mitigate tissue damage associated with excessive inflammation by promoting ferroptosis in activated immune cells, thereby restoring tissue homeostasis (Dai et al., 2025).

Conclusion

The interplay between the JAK/STAT signaling pathway and ferroptosis underscores the complexity of cellular regulation in cancer and other diseases. By understanding this relationship, researchers can develop targeted therapies that manipulate these pathways to enhance ferroptosis selectively, providing new strategies for overcoming drug resistance and improving patient outcomes in cancer treatment. Furthermore, the implications of targeting ferroptosis extend beyond oncology, offering potential therapeutic avenues in various diseases characterized by oxidative stress and inflammation.

References

1. Dai, Y., Cui, C., Jiao, D., & Zhu, X. (2025). JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases. Cancer Cell International, 25(1), 36. https://doi.org/10.1186/s12935-025-03681-6

2. Delle Monache, S., La Scaleia, B., & Lacquaniti, F. (2025). Psychophysical evidence for an internal model of gravity in the visual and vestibular estimates of vertical motion duration. Scientific Reports, 12(1), 94512. https://doi.org/10.1038/s41598-025-94512-1

3. Aris, K. D. P., Cofsky, J. C., Shi, H., Al-Sayyad, N., Ivanov, I. E., & Bryant, Z. (2025). Dynamic basis of supercoiling-dependent DNA interrogation by Cas12a via R-loop intermediates. Nature Communications, 16(1), 57703. https://doi.org/10.1038/s41467-025-57703-y